Lexicon Pharma (LXRX) Tops Q4 EPS by 3c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.24 -0.88%
Revenue Growth %: -78.9%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
CAN, UNFI, SUNB, More
Revenue Growth %: -78.9%
Financial Fact:
Consolidated net loss: -36.02M
Today's EPS Names:
CAN, UNFI, SUNB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.09), $0.03 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $26.55 million versus the consensus estimate of $7.16 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Starts Shake Shack (SHAK) at Outperform
- DraftKings (DKNG) PT Raised to $37 at Market Outperform by Citizens
- Morgan Stanley Downgrades Peloton Interactive (PTON) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
